Brian K. Link
YOU?
Author Swipe
View article: Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop Open
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although patients with FL have high response rates to therapy, most develop increasingly resistant disease. In addition, transformation into an aggressive lymphoma …
View article: Outcomes in the 2nd decade following follicular lymphoma (FL) diagnosis: Long-term follow-up from the university of Iowa/Mayo Clinic SPORE molecular epidemiology resource (MER)
Outcomes in the 2nd decade following follicular lymphoma (FL) diagnosis: Long-term follow-up from the university of Iowa/Mayo Clinic SPORE molecular epidemiology resource (MER) Open
Introduction: Outcomes for FL have markedly improved, and the 10-year (yr) overall survival (OS) for patients (pts) diagnosed in the rituximab era is about 80%. Historically, FL is the leading cause of death in the first decade after diagn…
View article: External validation of the early-stage classic Hodgkin lymphoma (cHL) international prognostication index (E-HIPI) in the german Hodgkin study group (GHSG) unfavorable clinical trials
External validation of the early-stage classic Hodgkin lymphoma (cHL) international prognostication index (E-HIPI) in the german Hodgkin study group (GHSG) unfavorable clinical trials Open
Background: Although progression-free survival (PFS) in early-stage (ES) classic Hodgkin Lymphoma (cHL) is high, there remains a subset of patients (pts) at higher risk of worse outcomes, particularly in those with unfavorable risk disease…
View article: FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting
FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting Open
Background: Prognostication for patients with non-transformed relapsed/refractory (R/R) follicular lymphoma (FL) is not well defined. Progression of disease within 24 months (POD24) and number of lines of prior therapy are commonly used to…
View article: Performance of molecular classifiers relative to the international prognostic index (IPI) for overall and event-free survival in diffuse large B-cell lymphoma (DLBCL)
Performance of molecular classifiers relative to the international prognostic index (IPI) for overall and event-free survival in diffuse large B-cell lymphoma (DLBCL) Open
Over the past decade, classification systems using high-throughput genetic data have been developed to identify molecular subtypes of DLBCL. Although not a primary goal, these classifiers were also proposed as prognostic factors in their r…
View article: Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma
Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma Open
Although follicular lymphoma (FL) typically follows an indolent course, patients with FL who experience early events, such as transformation or progression, have increased risk of death related to lymphoma. The FL24Cx is an algorithm based…
View article: Genetically determined body mass index is associated with diffuse large B‐cell lymphoma in polygenic and Mendelian randomization analyses
Genetically determined body mass index is associated with diffuse large B‐cell lymphoma in polygenic and Mendelian randomization analyses Open
Obesity has been associated with non‐Hodgkin lymphoma (NHL), but the evidence is inconclusive. We examined the association between genetically determined adiposity and four common NHL subtypes: diffuse large B‐cell lymphoma (DLBCL), follic…
View article: Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts Open
Follicular lymphoma (FL) 3B is considered an aggressive lymphoma, however recent studies have challenged this paradigm. Additional controversy involves the clinical implication of pure FL3B (FL3Bp) vs FL3B with concurrent diffuse large B c…
View article: Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma Open
Mantle cell lymphoma (MCL) is a genetically and clinically heterogeneous B-cell malignancy. We studied two MCL cohorts with differing treatment patterns: one enriched for immunochemotherapy, the other for chemotherapy alone. TP53 alteratio…
View article: Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐<scp>GemOx</scp>: A Multicenter Cohort Study
Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐<span>GemOx</span>: A Multicenter Cohort Study Open
Rituximab, gemcitabine, and oxaliplatin (R‐GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), but there are limited real‐world data. In a multicenter retrospective s…
View article: The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool Open
No abstract available
View article: Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma Open
Patients with r/r LBCL have unfavorable outcomes and need more effective treatment alternatives.
View article: Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium Open
Progression of disease within 24 months of initial immunochemotherapy (POD24) is a negative prognostic factor for patients with follicular lymphoma (FL). There is no standard treatment after POD24. Assembling an academic-based cohort from …
View article: Primary Central Nervous System Lymphoma Tumor Biopsies Show Heterogeneity in Gene Expression Profiles and Genetic Subtypes
Primary Central Nervous System Lymphoma Tumor Biopsies Show Heterogeneity in Gene Expression Profiles and Genetic Subtypes Open
Background Primary central nervous system lymphoma (PCNSL) is clinically challenging due to its location and small biopsy size, leading to a lack of comprehensive molecular and biologic description. We previously demonstrated that 91% of P…
View article: Real-World Predictors of Financial Toxicity in Patients with Lymphoma
Real-World Predictors of Financial Toxicity in Patients with Lymphoma Open
Background: Financial toxicity (FT), or the negative impact of medical expenses experienced by patients, is a known adverse effect of cancer treatment that result in worse health outcomes for patients. However, there is limited literature …
View article: Frontline R-CHOP and BR Have Similar Outcomes By SUVmax in Follicular Lymphoma
Frontline R-CHOP and BR Have Similar Outcomes By SUVmax in Follicular Lymphoma Open
Background: Positron emission tomography (PET) scan is the imaging modality of choice for initial staging and response assessment of follicular lymphoma (FL). Quantitative parameters such as standardized uptake value (SUV) have been invest…
View article: Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Open
Background: The Optimized Hemophagocytic Lymphohistiocytosis (HLH) Inflammatory (OHI, Zoref-Lorenz et al, Blood, 2022) index, defined by the combined elevation in serum soluble CD25 (sCD25) and ferritin, has emerged as a promising prognost…
View article: Understanding the Patient Perspective on Treatment Preferences for Follicular Lymphoma
Understanding the Patient Perspective on Treatment Preferences for Follicular Lymphoma Open
Background: Due to recent advances, patients with follicular lymphoma (FL) have multiple treatment options with high response rates and durability. However, there is a gap in understanding how patient preferences influence treatment select…
View article: <i>Molecular Subtyping of DLBCL Patients from the Oncology Research Information Exchange Network</i>
<i>Molecular Subtyping of DLBCL Patients from the Oncology Research Information Exchange Network</i> Open
Background: Simplified LymphPlex algorithm recently described molecular subclassification of DLBCL based on mutations of 35 genes and rearrangements of BCL2, BCL6, and MYC. Seven distinct genetic subtypes are included: TP53Mut, MCD-like (c…
View article: Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study Open
Background: Rituximab, gemcitabine, and oxaliplatin (R-GemOx) is a commonly utilized chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), especially for patients ineligible for autologous stem …
View article: Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature Open
Marginal zone lymphoma (MZL) includes extranodal MZL (EMZL), splenic MZL (SMZL), and nodal MZL (NMZL) subtypes. Histologic transformation (HT) to large B-cell lymphomas is well documented but with a large variability in published cumulativ…
View article: Transformation of marginal zone lymphoma to Hodgkin lymphoma
Transformation of marginal zone lymphoma to Hodgkin lymphoma Open
Marginal zone lymphomas (MZLs) make up 5% to 10% of non-Hodgkin lymphomas. In the United States, extranodal MZL (EMZL) is the most common subtype (61%), followed by nodal MZL (NMZL; 30%) and splenic MZL (SMZL; 9%), with an increased incide…
View article: Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis Open
Recent introduction of 2 different lymphoma classifications has raised concerns about consistency in diagnosis, management, and clinical trial enrollment. Data from a large cohort reflecting real-world clinical practice suggest that differ…